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pen access Abstract Diabetes mellitus (DM) is a group of metabolic disorders characterized by chronic
hyperglycemia resulting from relative or absolute insulin deﬁciency with or without insulin resis-
tance. As anxiolytics may have inﬂuence on glycemic control in diabetics, the present study was con-
ducted to investigate the possible inﬂuence of buspirone in streptozotocin-induced DM and its
possible interactions with rosiglitazone, an insulin sensitizer. Diabetes was induced by streptozoto-
cin (50 mg/kg i.p.). Rats were classiﬁed into ﬁve groups namely: normal control, diabetic control,
rosiglitazone (10 mg/kg p.o.), buspirone (20 mg/kg i.p.) or combination of both rosiglitazone and
buspirone, respectively. All groups received daily treatments for 2 weeks after induction of DM
including the normal group which received 1% Tween 80. There was no signiﬁcant interaction
between rosiglitazone and buspirone on the levels of serum glucose, insulin and C-peptide or liver
glycogen content. Similarly, no interaction was observed between rosiglitazone and buspirone on
oxidative stress parameters including serum malondialdehyde and blood glutathione levels or blood
superoxide dismutase activity. In conclusion, the present study revealed that co-administration of2930616; fax: +20 0822317958.
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74 W.R. Mohamed et al.buspirone with rosiglitazone does not produce serious reactions and buspirone can be safely
administered as an anxiolytic in diabetic patients treated with rosiglitazone.
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Diabetes mellitus (DM) is a group of metabolic disorders char-
acterized by hyperglycemia resulting from defects in insulin
secretion, insulin action, or both.1 Diabetic patients experience
many stresses such as dietary adjustment, frequent blood
checks, insulin injections and other complications of diabe-
tes.2,3 These stresses affect quality of life, social relationship,
work and mental health status of the patient.4
Several animal studies conﬁrmed that stress produces
hyperglycemia.5 Other studies suggest that stress has a role
in the induction of insulin resistance in different tissues.6,7
Moreover, antianxiety drugs such as diazepam and alprazolam
have effects on glycemic control in diabetic patients.8,9
Anxiety increases the production of reactive oxygen species
(ROS) through stimulation of damaging pathways leading to
lipid peroxidation, protein oxidation, DNA damage and cell
death.10–12
Rosiglitazone is an insulin sensitizer used in the treatment
of type 2 diabetes mellitus (T2DM). It is a member of thiazo-
lidinedione class of drugs, which are commonly referred to as
‘‘glitazones’’.13 Rosiglitazone exerts its clinical effect through
the peroxisome proliferator-activated receptor-c (PPAR-c).
Buspirone, 5HT1A receptor agonist, is widely used in
anxiolytic therapy.14,15 As anxiolytics have an effect on glyce-
mic control in diabetics, the present study was conducted to
investigate the possible inﬂuence of buspirone in streptozoto-
cin (STZ)-induced DM and its possible interactions with
rosiglitazone.
Parameters measured to fulﬁll this aim included effects on
serum levels of glucose, insulin and C-peptide as well as liver
glycogen content. As oxidative stress appears to be a common
link between DM and anxiety, the study also included assess-
ment of certain oxidative stress biomarkers namely, serum
malondialdehyde (MDA) and blood glutathione (GSH) levels
as well as blood superoxide dismutase (SOD) activity in dia-
betic rats.
2. Material and methods
2.1. Animals
Adult male Wistar rats weighing (120–160 g) obtained from
the animal house of faculty of Pharmacy, Beni-Suef University
were used in the current study. They were housed 10 per cage
and maintained at 25 ± 2 C with free access to water and
food, under a 12/12 h light–dark cycle. All procedures in this
study were carried out according to guidelines of Ethics Com-
mittee of Faculty of Pharmacy, Cairo University.
2.2. Drugs and chemicals
Rosiglitazone and buspirone were provided as a gift from
APEX Company (Egypt) and ALKAN Company (Egypt),respectively. Each was suspended in 1% Tween 80. Rosiglitaz-
one was orally administered in a dose of 10 mg/kg16 whereas
buspirone was i.p. administered in a dose of 20 mg/kg.17
STZ was purchased from Sigma–Aldrich (USA).
2.3. Induction of experimental diabetes
Diabetes was induced in 12 h fasted rats with single i.p. injec-
tion of STZ (50 mg/kg)18 dissolved in citrate buffer (0.01 M,
pH 4.5). Normal control group was injected with citrate buffer
alone. Animals were considered diabetic when their blood glu-
cose level exceeded 250 mg/dl19 and were included in the study
after 72 h of STZ injection.
2.4. Experimental design
In addition to the normal group, diabetic rats were randomly
classiﬁed into four groups each consisting of eight rats. The ﬁrst
group received 1% Tween 80 (control diabetic). The remaining
three groups received rosiglitazone (10 mg/kg p.o.), buspirone
(20 mg/kg i.p.) or combination of both rosiglitazone and buspi-
rone, respectively. All groups received daily treatments for
2 weeks.
At the end of the experiment rats were fasted overnight,
blood was collected and serum was prepared and used for var-
ious biochemical estimations. Animals were sacriﬁced and liver
isolated for liver glycogen content determination.
2.5. Biochemical estimations
Serum glucose level was estimated using glucose kit (spinreact,
Spain) and expressed as mg/dl whereas serum insulin and C-
peptide levels were assayed using radioimmunoassay kits
(Coat-a-Count kit-DPC, Los Angeles, CA, USA) and ex-
pressed as lIU/ml and ng/ml, respectively.
Liver glycogen was estimated20 and expressed as mg/g wet
tissue.
Serum lipid peroxides level was estimated by determina-
tion of the level of thiobarbituric acid reactive substances
(TBARS) that were measured as MDA21 and expressed as
nmol/ml. Blood SOD was estimated using the pyrogallol
method22 and expressed as ug/ml. Blood GSH was estimated
according to the method of Beutler et al.23 and expressed as
mg%.
2.6. Statistical analysis
The values of the measured parameters were presented as
mean ± SE. Comparisons between different treatments were
carried out using one way analysis of variance (ANOVA)
followed by Tukey–Kramer multiple comparisons test. Dif-
ferences were considered statistically signiﬁcant when
p< 0.05.
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Figure 1 Effect of two weeks administration of rosiglitazone
(Ros.), buspirone (Bus.) or their combination on liver glycogen in
diabetic rats. Experimental diabetes was induced by single i.p.
injection of 50 mg/kg streptozotocin (STZ). Each value represents
the mean of 6–8 experiments ± SE of the mean. *Signiﬁcantly
different from normal control at p< 0.05. aSigniﬁcantly different
from diabetic control at p< 0.05.
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3.1. Effect of two weeks administration of rosiglitazone,
buspirone or their combination on serum glucose, insulin
and C-peptide levels in diabetic rats
STZ signiﬁcantly increased serum glucose level and decreased
serum insulin and serum C-peptide levels of rats. Rosiglitazone
and buspirone signiﬁcantly decreased serum glucose level to
40.29% and 35.82% of the diabetic control value, respectively.
The combination of buspirone with rosiglitazone did not sig-
niﬁcantly change the effect of rosiglitazone on serum glucose
level.
Treatment with rosiglitazone, buspirone or their combina-
tion did not signiﬁcantly affect serum insulin and C-peptide
levels as compared to the diabetic control value (Table 1).
3.2. Effect of two weeks administration of rosiglitazone,
buspirone or their combination on liver glycogen content
in diabetic rats
STZ signiﬁcantly decreased liver glycogen content of rats. Ros-
iglitazone and buspirone signiﬁcantly elevated liver glycogen
content to 219.76% and 195.72% of the diabetic control value,
respectively. The combination of buspirone with rosiglitazone
did not signiﬁcantly change the effect of rosiglitazone on liver
glycogen content (Fig. 1).
3.3. Effect of two weeks administration of rosiglitazone,
buspirone or their combination on oxidative stress biomarkers
in diabetic rats
STZ signiﬁcantly increased serum lipid peroxides of rats. Ros-
iglitazone and buspirone signiﬁcantly decreased serum lipid
peroxides to 52.90% and 49% of the diabetic control value,
respectively. Combination of buspirone with rosiglitazone
did not signiﬁcantly change the effect of rosiglitazone on ser-
um lipid peroxides (Fig. 2).
STZ signiﬁcantly decreased blood GSH of rats. Rosiglitaz-
one and buspirone signiﬁcantly elevated blood GSH to
181.21% and 213.84% of the diabetic control value, respec-
tively. The combination of buspirone with rosiglitazone was
not signiﬁcantly different when compared to rosiglitazone
monotherapy (Fig. 3).
STZ signiﬁcantly decreased blood SOD of rats. Rosiglitaz-
one and buspirone signiﬁcantly elevated blood SOD to 144.2%Table 1 Effect of two weeks administration of rosiglitazone, buspiro
levels in diabetic rats.
Drugs & doses Parameters
Serum glucose (mg/dl)
Normal control (2% Tween 80) 74.50 ± 2.92
Diabetic control (2% Tween 80) 392.2* ± 12.41
Rosiglitazone (10 mg/kg) 158.0a ± 10.71
Buspirone (20 mg/kg) 140.5a ± 11.41
Rosiglitazone + Buspirone 127a ± 10.74
Each value represents the mean of 6–8 experiments ± SE of the mean. E
streptozotocin.
* Signiﬁcantly different from normal control at p< 0.05.
a Signiﬁcantly different from diabetic control at p< 0.05.and 151.72% of the diabetic control value, respectively. The
combination of buspirone with rosiglitazone was not signiﬁ-
cantly different when compared to rosiglitazone monotherapy
(Fig. 4).
4. Discussion
The present results revealed that STZ signiﬁcantly increased
blood glucose level and lowered serum insulin as well as serum
C-peptide levels in rats. STZ is a diabetogenic agent24 that
causes toxicity to b-cells of the pancreas.25,26 Rosiglitazone ex-
erted signiﬁcant hypoglycemic effects in the present study.
Similarly, other investigators showed that rosiglitazone signif-
icantly decreased serum glucose level without affecting serum
insulin or serum C-peptide levels in STZ-induced diabetic sub-
jects or rats.27–29
Glucose lowering effect of rosiglitazone is attributed to
its ability to reduce hyperglycemia by improving insulinne or their combination on serum glucose, insulin and C-peptide
Serum insulin (lIU/ml) Serum C-peptide (ng/ml)
6.62 ± 0.27 1.05 ± 0.05
2.93* ± 0.05 0.27* ± 0.03
3.28 ± 0.048 0.35 ± 0.03
3.38 ± 0.05 0.33 ± 0.01
3.15 ± 0.08 0.30 ± 0.01
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Figure 2 Effect of two weeks administration of rosiglitazone
(Ros.), buspirone (Bus.) or their combination on serum thiobar-
bituric acid reactive substances (TBARS) in diabetic rats. Exper-
imental diabetes was induced by single i.p. injection of 50 mg/kg
streptozotocin (STZ). Each value represents the mean of 6–8
experiments ± SE of the mean. *Signiﬁcantly different from
normal control at p< 0.05. aSigniﬁcantly different from diabetic
control at p< 0.05.
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Figure 3 Effect of two weeks administration of rosiglitazone
(Ros.), buspirone (Bus.) or their combination on blood reduced
glutathione (GSH) level in diabetic rats. Experimental diabetes
was induced by single i.p. injection of 50 mg/kg streptozotocin
(STZ). Each value represents the mean of 6–8 experiments ± SE
of the mean. *Signiﬁcantly different from normal control at
p< 0.05. aSigniﬁcantly different from diabetic control at
p< 0.05.
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Figure 4 Effect of daily twoweeks administration of rosiglitazone
(Ros.), buspirone (Bus.) or their combination on blood superoxide
dismutase (SOD) activity in diabetic rats. Experimental diabetes
was induced by single i.p. injection of 50 mg/kg streptozotocin
(STZ). Each value represents the mean of 6–8 experiments ± SE of
the mean. *Signiﬁcantly different from normal control at p< 0.05.
aSigniﬁcantly different from diabetic control at p< 0.05.
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Thiazolidinediones increase adiponectin release from fat cells;thus enhancing insulin sensitivity in liver and muscle32 leading
to increased fatty acid uptake, lipogenesis and glucose uptake
as well as reduced gluconeogenesis in liver.33 In vitro, rosiglit-
azone has no effect on insulin secretion from pancreatic
islets.34
Treatment of diabetic rats with buspirone, in the current
study, signiﬁcantly reduced serum glucose level but did not al-
ter serum insulin or serum C-peptide levels. It was reported
that buspirone reduced glucose-induced hyperglycemia and
facilitated glucose-induced hyperinsulinemia.35 Studies re-
vealed that buspirone36,37 and 5-HT agonists38,39 produced a
signiﬁcant fall in postprandial blood glucose level without
affecting insulin secretion. The possible mechanism of action
may be due to an increase in glucose uptake across the cell
membrane in skeletal muscle40 through non-insulin dependent
pathways.36,37 No interaction was observed between buspirone
and rosiglitazone on serum glucose, insulin and C-peptide
levels of STZ-induced diabetic rats. This indicates that the
co-administration of buspirone with rosiglitazone does not
produce serious reactions.
Present results showed that rosiglitazone signiﬁcantly ele-
vated liver glycogen content of diabetic rats. Other investiga-
tors showed that rosiglitazone41 and troglitazone increased
glycogen synthesis in skeletal muscle of type 2 diabetic42 and
in insulin resistant obese subjects.43 The effect of rosiglitazone
on liver glycogen could be explained through improvement of
glycemic control by enhancing insulin-stimulated glucose
disposal.44–46 The increase in insulin sensitivity is the result
of enhanced insulin action in liver,44,47 skeletal muscle48 and
adipose tissue.49
Similarly, treatment with buspirone signiﬁcantly increased
liver glycogen content of diabetic rats and its combination with
Possible modulation of the antidiabetic effect of rosiglitazone by buspirone 77rosiglitazone did not signiﬁcantly improve the effects of the
latter on liver glycogen content. Concerning the effects of
buspirone, it could be related to increased glycogen synthetase
activity or increased sensitivity of hepatic insulin receptors.50
STZ injection in the present work resulted in signiﬁcant in-
crease in serum MDA level parallel to a decrease in blood
GSH level and SOD activity. The present results are in accor-
dance with those obtained by other investigators.51,52 Several
studies demonstrated that free radicals are excessively gener-
ated in hyperglycemia through many pathways including glu-
cose auto-oxidation,53 protein glycation54 and excessive
activation of polyol pathway.55
In the current study, treatment of STZ-diabetic rats with
rosiglitazone signiﬁcantly reduced serum MDA level and in-
creased blood GSH level and SOD activity of diabetic rats.
The present results are in accordance with data obtained by
other investigators.52,56 The antioxidant activity of rosiglitaz-
one might be mediated through its effect on mitochondrial
respiratory chain which is the major source of ROS that are
generated mainly at complexes I and III of respiratory chain.57
Rosiglitazone inhibits both complex I58 and complex III activ-
ities59 affecting both electron transport and superoxide anion
generation. Moreover, (mito-NEET), a novel mitochondrial
target protein for PPAR-c agonists, has been identiﬁed60 and
it is associated with several components of complex III,
explaining how PPAR-c agonists binding to mito-NEET could
selectively block different mitochondrial targets. Other studies
have showed that several antioxidant enzymes, such as SOD-
1,61 SOD-262 and catalase are target genes of PPAR-c.63
In a similar fashion, treatment of diabetic rats with buspi-
rone signiﬁcantly reduced serum MDA level; meanwhile it im-
proved blood GSH level and SOD activity. Similar results were
obtained by other investigators.64 Other studies showed that
buspirone has a pharmacologically active metabolite which
could have antioxidant activity.65,66 No signiﬁcant interaction
was observed between buspirone and rosiglitazone on serum
MDA level, blood GSH level and SOD activity.
In the present study, despite the fact that both rosiglitazone
and buspirone favorably affected diabetic and oxidative stress
biomarkers, no additive effect was observed upon their combi-
nation. This may be attributed to the use of full therapeutic
dose of both agents. It is possible that if smaller doses were
used, an additive effect would be noticed. Further investiga-
tions may be required to study this possibility.
In conclusion, the present study revealed that buspirone did
not signiﬁcantly affect the antidiabetic action of rosiglitazone.
This indicates that co-administration of buspirone with rosig-
litazone does not produce serious reactions and buspirone can
be administered as anxiolytic in diabetic patients treated with
rosiglitazone.References
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